VAIA
KRTX

Virtus Alternative Investment Advisers’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-71
Closed -$7K – 248
2020
Q4 		$7K Sell
71
-68
-49% -$6.3K 0.1% 160
2020
Q3 		$11K Buy
+139
New +$11.8K 0.2% 233

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Virtus Alternative Investment Advisers's KRTX Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2021, closing a stake of 71 shares — an estimated $7K sold.

Virtus Alternative Investment Advisers first reported a position in KRTX in Q3 2020 and held it in 2 quarters. The position peaked at $11K in Q3 2020. 157 funds tracked by Wall St. Rank hold KRTX as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 71 Karuna Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $7K.
  • Virtus Alternative Investment Advisers first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Virtus Alternative Investment Advisers's Karuna Therapeutics, Inc. Common Stock position peaked at $11K in Q3 2020.
  • 157 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.